menu
    • menu
    [{"orgOrder":0,"company":"Onconic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||P-CAB","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Onconic Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Onconic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Onconic Therapeutics","sponsor":"Livzon Pharmaceutical Group","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Zastaprazan","moa":"||P-CAB","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Onconic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconic Therapeutics \/ Livzon Pharmaceutical Group","highestDevelopmentStatusID":"10","companyTruncated":"Onconic Therapeutics \/ Livzon Pharmaceutical Group"},{"orgOrder":0,"company":"Onconic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Onconic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Onconic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Onconic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Onconic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Onconic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Onconic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Onconic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Onconic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Onconic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Onconic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Onconic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Onconic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Onconic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Amoxicillin","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Onconic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Onconic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Onconic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"5-Fluorouracil","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Onconic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Onconic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Onconic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Onconic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Onconic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Onconic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Onconic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Aceclofenac","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Onconic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Onconic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Onconic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Onconic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Onconic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Onconic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Onconic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Onconic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Onconic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Onconic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Onconic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Onconic Therapeutics","sponsor":"Jeil Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Onconic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Onconic Therapeutics \/ Jeil Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Onconic Therapeutics \/ Jeil Pharmaceutical Co., Ltd"}]

    Find Clinical Drug Pipeline Developments & Deals by Onconic Therapeutics

    Menu

    Onconic Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Onconic Therapeutics

                            South Korea arrow
                            EPSC
                            Not Confirmed

                            Onconic Therapeutics

                            South Korea arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JP-1366,Inapplicable

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 03, 2024

                            Lead Product(s) : JP-1366,Inapplicable

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Onconic Therapeutics

                            South Korea arrow
                            EPSC
                            Not Confirmed

                            Onconic Therapeutics

                            South Korea arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zastaprazan Citrate,Inapplicable

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Onconic Receives MFDS Approval for JAQBO, a New GERD Treatment

                            Details : Jaqbo (zastaprazan citrate) is a next-generation potassium competitive blocker, small molecule drug candidate. It is being evaluated for the treatment of gastroesophageal reflux disease in adults.

                            Product Name : Jaqbo

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 25, 2024

                            Lead Product(s) : Zastaprazan Citrate,Inapplicable

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Onconic Therapeutics

                            South Korea arrow
                            EPSC
                            Not Confirmed

                            Onconic Therapeutics

                            South Korea arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JP-1366,Inapplicable

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Trial to Evaluate the Safety and Pharmacokinetics of JP-1366 in Healthy Adult Volunteers

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 18, 2023

                            Lead Product(s) : JP-1366,Inapplicable

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Onconic Therapeutics

                            South Korea arrow
                            EPSC
                            Not Confirmed

                            Onconic Therapeutics

                            South Korea arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zastaprazan,Inapplicable

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Livzon Pharmaceutical Group

                            Deal Size : $127.5 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Livzon Acquires Rights to GERD Therapy from Onconic for $127.5 Million

                            Details : Zastaprazan is a P-CAB (potassium-competitive acid-blocking) candidate, a class of drugs that is replacing existing PPIs (proton pump inhibitors) for peptic ulcer disease, including GERD. Livzon will have rights to JP 1366 (zastaprazan) in China, Taiwan,...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : $15.0 million

                            March 14, 2023

                            Lead Product(s) : Zastaprazan,Inapplicable

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Livzon Pharmaceutical Group

                            Deal Size : $127.5 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Onconic Therapeutics

                            South Korea arrow
                            EPSC
                            Not Confirmed

                            Onconic Therapeutics

                            South Korea arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JP-1366,Inapplicable

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Trial to Evaluate Food-Effects on Pharmacokinetics and Pharmacodynamics of Oral Single Dose of JP-136...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 03, 2023

                            Lead Product(s) : JP-1366,Inapplicable

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Onconic Therapeutics

                            South Korea arrow
                            EPSC
                            Not Confirmed

                            Onconic Therapeutics

                            South Korea arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JPI-547,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 26, 2022

                            Lead Product(s) : JPI-547,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Onconic Therapeutics

                            South Korea arrow
                            EPSC
                            Not Confirmed

                            Onconic Therapeutics

                            South Korea arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JP-1366,Inapplicable

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 07, 2022

                            Lead Product(s) : JP-1366,Inapplicable

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Onconic Therapeutics

                            South Korea arrow
                            EPSC
                            Not Confirmed

                            Onconic Therapeutics

                            South Korea arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JP-1366,Inapplicable

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 05, 2022

                            Lead Product(s) : JP-1366,Inapplicable

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Onconic Therapeutics

                            South Korea arrow
                            EPSC
                            Not Confirmed

                            Onconic Therapeutics

                            South Korea arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JPI-547,Fluorouracil,Calcium Folinate,Irinotecan Hydrochloride,Oxaliplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 25, 2022

                            Lead Product(s) : JPI-547,Fluorouracil,Calcium Folinate,Irinotecan Hydrochloride,Oxaliplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Onconic Therapeutics

                            South Korea arrow
                            EPSC
                            Not Confirmed

                            Onconic Therapeutics

                            South Korea arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JP-1366,Amoxicillin Trihydrate,Clarithromycin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Drug-drug Interactions and Safety Among JP-1366, Amoxicillin, and Clarithromycin in Healthy Volunteers

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 18, 2022

                            Lead Product(s) : JP-1366,Amoxicillin Trihydrate,Clarithromycin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth